A Fresh Trial on Magnesium for Everyday Poor Sleepers

Rather than studying older adults with diagnosed insomnia, this pilot trial recruited 31 adults with an average age of 46 who simply described their sleep as poor, closer to the everyday, midlife audience most curious about magnesium. Each participant took either one gram of a magnesium supplement or a placebo daily for two weeks, then, after a break, switched to the other condition, so each person served as their own comparison. Sleep quality and mood both improved significantly during the magnesium phase compared with placebo, with full adherence and no adverse effects reported.

As a pilot study of just 31 people over a relatively short two-week window, this is early-stage evidence rather than a definitive answer, and the crossover design, while a strength for controlling individual variation, can't rule out carryover effects between phases. The researchers themselves called for longer trials in more varied populations. Its value is relevance: it's one of the few controlled trials testing magnesium in the kind of person, midlife, generally healthy, mildly poor-sleeping, who actually reaches for it.